Symbiotec Pharmalab Authorizes KMPs to Determine Materiality of Events
Symbiotec Pharmalab Limited has authorized its Chairman & Managing Director, CFO, and Company Secretary to determine the materiality of events and make disclosures to stock exchanges as per SEBI regulations.
This is a standard corporate governance procedure mandated by SEBI regulations and does not involve any significant financial or operational changes for the company.
The announcement is a routine regulatory compliance action and does not contain any new financial information or strategic business updates that would impact the company's stock.
Symbiotec Pharmalab Limited has announced the authorization of its Key Managerial Personnel (KMPs) to determine the materiality of events or information and to make disclosures to the stock exchanges. This action is in compliance with Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The authorized KMPs include Anil Satwani, the Chairman & Managing Director; Raghavender Ramachandran, the Chief Financial Officer; and Salil Jain, the Company Secretary and Compliance Officer. Their contact details, including address, phone number, and email, have been provided for disclosure purposes.
This intimation is for the information and records of the stock exchanges.
A plain-language summary of a public exchange filing by Symbiotec Pharmalab Limited. Read the original for the full detail.